Could a targeted drug re-sensitize resistant breast cancer?
NCT ID NCT07706179
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This pilot trial tests whether adding the drug alisertib to usual care can help people with advanced HR+/HER2+ breast cancer whose disease has become resistant to standard treatments. Researchers want to see if alisertib can block communication between hormone receptors and HER2, and whether certain genetic markers predict response. Ten participants receive alisertib in cycles alongside their ongoing therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a drug called alisertib
- What this could lead to
- If successful, this could point toward a new treatment option for people with HR+/HER2+ breast cancer whose disease has stopped responding to standard therapy.
- What could go wrong
- This is a very small pilot study with only 10 participants, so results may not apply to everyone. The drug may cause side effects and may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug outsmart resistant breast cancer?
- Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
- Could two years of hormone therapy be enough for some breast cancers?
- New drug targets Hard-to-Treat breast cancer in advanced stage
- Could a simple blood test let some breast cancer patients stop treatment?
- New drug cocktail aims to outsmart resistant breast cancer